



PerkinElmer Expands Chromatography Offering With New Liquid Chromatography Autosampler

NEW ORLEANS – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today at PITTCON[®] 2008, Booth #2555, announced the introduction of the Series 225 LC Autosampler to enable customers to meet the demanding needs for automation, quantitation and throughput in analyses using liquid chromatography (LC). The autosampler is fully integrated into the PerkinElmer Series 200 family of LC products running on TotalChrom[®] software to support pharmaceutical, food and beverage, environmental, materials characterization and chemical industry research and testing.

“The Series 225 LC Autosampler was designed to enable customers to gain improved throughput,” said Eric Ziegler, Vice President of Chromatography, PerkinElmer Life and Analytical Sciences. “It also provides functionalities in the pre-injection phase, minimizing user intervention at a stage where reliability of operations can directly affect the results of the analysis. Additionally, temperature-controlled sample compartments improve application flexibility.”

Ziegler noted that the Series 225 LC Autosampler was also designed for ease of maintenance and serviceability. “The result is uncompromised quantitative analysis in liquid chromatography which contributes to greater peace of mind,” Ziegler said.

For more information on the Series 225 LC Autosampler, visit www.perkinelmer.com/Series225AS.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

“PITTCON” is a registered trademark of its owner.

For further information regarding PerkinElmer, please contact:

Media Contact:
Ellen Wein
(412) 456-0986

or
Lesley Sillaman
(412) 456-7839